Andexanet alfa for acute major bleeding associated with factor Xa inhibitors. Available at: Accessed December 12, 2018.Ĭonnolly SJ, Milling TJ, Eikelboom JW, et al. Andexxa (coagulation factor Xa (recombinant), inactivated-zhzo): US Prescribing Information. Andexanet alfa, a universal antidote under development for factor Xa inhibitors, reverses rivaroxaban-induced inhibition of thrombin generation initiated by the intrinsic coagulation pathway independent of TFPI. Andexanet alfa is approved (FDA accelerated approval EMA conditional approval) as the first specific reversal agent for factor Xa (FXa) inhibitor-associated uncontrolled or life-threatening bleeding. A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. Apixaban versus warfarin in patients with atrial fibrillation. Granger CB, Alexander JH, McMurray JJV, et al.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |